Key Secondary Efficacy Endpoint Clause Samples
Key Secondary Efficacy Endpoint. The key secondary endpoint of Investigator-assessed DOR will be estimated using ▇▇▇▇▇▇-▇▇▇▇▇ method for survival function estimate. The initial analysis of DOR will be conducted at the time of primary analysis of ▇▇▇. An updated analysis of DOR will be conducted 12 months after the primary analysis of ▇▇▇, at the end of the study.
Key Secondary Efficacy Endpoint. The change from baseline in eGFR in bardoxolone methyl-treated patients relative to placebo at Week 52 following a 4-week drug treatment withdrawal period.